Ton Berkien, a former executive at Takeda, is joining Nuevolution A/S of Denmark as chief business officer to lead the commercial development of the company’s preclinical compounds in the areas of oncology and inflammation. Mr Berkien was most recently senior director of corporate development at Takeda Pharmaceuticals International GmbH in Switzerland where he was responsible for several merger and acquisition transactions in the US, Europe and several countries in the developing world. Prior to this, he held a similar position at Nycomed Pharmaceuticals. Mr Berkien has a BA degree in economics from the Saxion University of Applied Science in the Netherlands and an advanced degree from the Harvard Business School.
Nuevolution announced the appointment on 9 December. It will take effect on 1 January 2014.
Copyright 2013 Evernow Publishing Ltd